Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Rhea-AI Summary

Adaptimmune Therapeutics (Nasdaq:ADAP) announced the upcoming presentation of initial preclinical data on its HLA Independent TCR (HiT) targeting mesothelin, co-developed with Astellas, at the ASGCT meeting. This will occur on May 11, 2021, during the Cancer - Immunotherapy session, with abstract #641 published online. Adaptimmune focuses on cell therapies for cancer, utilizing its SPEAR T-cell platform to combat various solid tumors. The release contains forward-looking statements, indicating potential risks related to product development and regulatory processes.

Positive

• Initial preclinical data for HiT targeting mesothelin to be presented at ASGCT.
• Collaboration with Astellas may enhance development and market potential.

Negative

• Forward-looking statements indicate risks related to product development and regulatory challenges.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference.

• Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641)
• Poster Presentation: Tuesday May 11, 2021 8:00 a.m. - 10:00 a.m. EDT during the Cancer - Immunotherapy, Cancer Vaccines Session

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com

FAQ

What is the purpose of the HiT targeting mesothelin trial by Adaptimmune?

The HiT trial aims to evaluate the effectiveness of a novel T-cell receptor targeting mesothelin in cancer treatment.

When will the preclinical data for HiT targeting mesothelin be presented?

The data will be presented on May 11, 2021, during the ASGCT meeting.

How does Adaptimmune's SPEAR T-cell platform work?

The SPEAR T-cell platform enables the engineering of T-cells to specifically target and destroy cancer cells across various solid tumors.

What risks are associated with Adaptimmune's forward-looking statements?

The risks involve uncertainties in product development costs and regulatory approvals, which may impact clinical trial success.

What is the significance of the ASGCT meeting for Adaptimmune?

The ASGCT meeting is significant as it showcases Adaptimmune's advancements in cancer immunotherapy to industry peers and potential investors.